Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
Abstract Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and co...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-04-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.3900 |
| id |
doaj-73a29b3380ad4025b924e4d2606942f9 |
|---|---|
| record_format |
Article |
| spelling |
doaj-73a29b3380ad4025b924e4d2606942f92021-05-15T18:35:44ZengWileyClinical Case Reports2050-09042021-04-01941905191210.1002/ccr3.3900Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusionFabián Pitoia0Division of Endocrinology, Hospital de Clínicas University of Buenos Aires Buenos Aires ArgentinaAbstract Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with RAI‐R‐differentiated thyroid cancer who might otherwise have few treatment options.https://doi.org/10.1002/ccr3.3900iodine uptake and iodine metabolismthyroid cancer‐clinicalthyroid cancer‐genetics |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Fabián Pitoia |
| spellingShingle |
Fabián Pitoia Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion Clinical Case Reports iodine uptake and iodine metabolism thyroid cancer‐clinical thyroid cancer‐genetics |
| author_facet |
Fabián Pitoia |
| author_sort |
Fabián Pitoia |
| title |
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion |
| title_short |
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion |
| title_full |
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion |
| title_fullStr |
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion |
| title_full_unstemmed |
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion |
| title_sort |
complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an etv6‐ntrk3 gene fusion |
| publisher |
Wiley |
| series |
Clinical Case Reports |
| issn |
2050-0904 |
| publishDate |
2021-04-01 |
| description |
Abstract Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with RAI‐R‐differentiated thyroid cancer who might otherwise have few treatment options. |
| topic |
iodine uptake and iodine metabolism thyroid cancer‐clinical thyroid cancer‐genetics |
| url |
https://doi.org/10.1002/ccr3.3900 |
| work_keys_str_mv |
AT fabianpitoia completeresponsetolarotrectinibtreatmentinapatientwithpapillarythyroidcancerharboringanetv6ntrk3genefusion |
| _version_ |
1721440605064658944 |